Advances in Pompe Disease Treatment and Emerging Therapies

Understanding Pompe Disease

The root cause of Pompe disease is mutations in the GAA gene, leading to a lack of functional enzyme necessary to break down glycogen.
The disease manifests in two primary forms: infantile-onset Pompe disease (IOPD) and late-onset Pompe disease (LOPD).
Late-onset Pompe disease (LOPD) progresses more slowly, affecting respiratory and skeletal muscles, often leading to mobility and breathing difficulties.

Current Standard of Care: Enzyme Replacement Therapy (ERT)

ERT has been the primary treatment for Pompe disease since the approval of alglucosidase alfa (Myozyme/Lumizyme) by Sanofi. While ERT helps manage symptoms and prolong survival, it has several limitations:
✔️ Requires lifelong infusions
✔️ Limited ability to completely clear glycogen buildup
✔️ Some patients develop an immune response, reducing efficacy

Emerging Therapies in the Pompe Disease Pipeline

Next-Generation ERTs

Newer enhanced ERTs with improved muscle uptake and longer half-life are being developed.
Avalglucosidase alfa (Nexviazyme) – A second-generation ERT by Sanofi, approved in 2021, offers better muscle targeting.

Gene Therapy

AAV-based gene therapy aims to provide a one-time, long-term solution by introducing a functional copy of the GAA gene.
Companies like Spark Therapeutics, Amicus Therapeutics, and Astellas Gene Therapies are actively developing gene therapy candidates for Pompe disease.

Substrate Reduction Therapy (SRT)

This approach reduces glycogen buildup by inhibiting enzymes responsible for glycogen synthesis.
SRT is being explored as a complementary therapy to ERT.

Chaperone Therapy

Molecular chaperones stabilize the defective GAA enzyme, enhancing its activity.
Amicus Therapeutics’ AT-GAA is a combination of ERT and a chaperone molecule, showing promising clinical trial results.

Future Outlook: What’s Next for Pompe Disease Treatment?

Gene therapy holds the potential for a curative approach, reducing the burden of frequent ERT infusions.
Combination therapies (ERT + gene therapy or SRT) could enhance long-term patient outcomes.
Advancements in personalized medicine may improve treatment responses based on genetic mutations and disease progression.

With the Pompe disease pipeline rapidly evolving, these innovations may soon redefine the standard of care, offering longer-lasting, more effective treatments for both infantile and late-onset Pompe disease patients.

Latest Reports Offered By DelveInsight: